Dr. Shiller on the Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

Publication
Video
Supplements and Featured PublicationsAdvancing Applications for Antibody-Drug Conjugates in Breast Cancer
Volume 1
Issue 1

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Michelle Shiller, DO, AP/CP, MGP, member, the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses the role of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with HER2-positive breast cancer.

In May 2022, the FDA granted regular approval to trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti–HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within 6 months of therapy completion.

Although HER2 has long been an important biomarker in breast cancer, a deeper understanding of the biomarker is important as new agents continue to emerge, Shiller says. Data from the phase 3 DESTINY-Breast02 (NCT03523585) and DESTINY-Breast03 (NCT03529110) trials have shown that patients who historically have had good responses with trastuzumab (Herceptin) can derive a greater benefit with trastuzumab deruxtecan, Shiller adds.

HER2-positive disease is defined as HER2 overexpression of 3+ with immunohistochemistry (IHC) or HER2 amplification of 2+ with IHC/ fluorescence in situ hybridization assays. These standards are used to identify patients who can benefit from HER2-targeted therapies, Shiller concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD